dementia-2017-posters-accepted-abstracts

12 / 33

Page 66
Notes:
conferenceseries.com
Volume 7, Issue 6 (Suppl) J Alzheimers Dis Parkinsonism, an open access journal
ISSN: 2161-0460 Dementia 2017
October 16-18, 2017
ALZHEIMER’S DISEASE & DEMENTIA
October 16-18, 2017 | Rome, Italy
9th International Conference on
Protective effect of Atorvastatin on D-galactose induced aging Model in Mice
Iman Fatemi
Rafsanjan University of Medical Sciences, Iran
Atorvastatin (Ator), competitive inhibitors of 3-hydroxymethyl-3-glutaryl-coenzyme-A reductase, is a cholesterol lowering
drug. Ator has been shown to have neuroprotective, antioxidant and anti-inflammatory properties making that a potential
candidate for the treatment of central nervous system (CNS) disorders. Here we assessed the effect of Ator on the D-galactose
(D-gal)-induced aging in mice. For this purpose, Ator (0.1 and 1 mg/kg/p.o.), was administrated daily in D-gal-received (500
mg/kg/p.o.) mice model of aging for six weeks. Anxiety-like behaviors and cognitive functions were evaluated by the elevated
plus-maze and novel object recognition tasks, respectively. Physical power was assessed by forced swimming capacity test.
Animals brains were analyzed for the superoxide dismutase (SOD) and brain-derived neurotrophic factor (BDNF). We found
that Ator decreases the anxiety-like behaviors in D-gal-treated mice. Also, our behavioral tests showed that Ator reverses the
D-gal induced learning and memory impairment. Furthermore, we found that Ator increases the physical power of D-gal-
treated mice. Our results indicated that the neuroprotective effect of Ator on D-gal induced neurotoxicity is mediated, at least
in part, by an increase in the SOD and BDNF levels. The results of present study suggest that Atro could be used as a novel
therapeutic strategy for the treatment of age-related conditions.
Biography
Iman Fatemi has started his PhD at the age of 28 years from Rafsanjan University of Medical Sciences. He has published more than 10 papers in reputed journals.
Iman Fatemi, J Alzheimers Dis Parkinsonism 2017, 7:6(Suppl)
DOI: 10.4172/2161-0460-C1-034